

SC House Bill 3934 SC Senate Bill 330

Labor. Commerce and Industry

Co-Sponsors: Representative Kevin Hardee (R-105) kevinhardee@schouse.gov (803) 212-6796

Representative Carla Schuessler (R-61) carlaschuessler (aschouse.gov (803) 212-6926

Banking and Insurance

Sponsor: Senator Mike Gambrell (R-4) mikegambrell@scsenate.gov (803) 212-6032

Co-Sponsor: Senator Jason Elliott (R-6) jasonelliott(@scsenate.gov (803)-212-6108

The Problem

In the commercial health insurance market, some patients are being forced to pay more out-of-pocket for their medicines due to an increase in hidden tactics that limit patient assistance such as, Accumulator Adjustment Programs (AAP), Alternative Funding Programs (AFP) and Copay Maximizer Programs (CMP).

What is an Accumulator Adjustment Program (AAP)?

AAPs are a type of scheme that health insurers and Pharmacy Benefit Managers (PBMs) use to prevent
manufacturer cost-sharing assistance from counting toward a patient's deductible or annual maximum outof-pocket (MOOP) costs.

5 out 6 of South Carolina Marketplace Plans and PBMs have adopted Polices, often referred to as "accumulator adjustment programs" that block assistance from counting towards a patient's deductible and maximum out-of-pocket limits.

What is a Copay Maximizer Program (CMP)?

- A Copay Maximizer Program targets and designates specific medicines with available manufacturer cost-sharing assistance as non-Essential Health Benefits (EHB) so that the Affordable Care Act (ACA) cost-sharing limitations do not apply.
- PBMs, health insurers, or third-party vendors then increase individual patient cost-sharing obligations to match the amount of the manufacturer costsharing assistance, and therefore exhaust, the full value of the assistance available for those medicines without counting the amount of the assistance towards the patient's deductible or maximum outof-pocket (MOOP) obligations.

What is an Alternative Funding Program (AFP)?

 AFPs are a type of cherry-picking strategy to avoid individuals with higher health risks, i.e., individuals with preexisting conditions, and shift coverage onto resources intended for disadvantaged populations.

144-1 Voice Vote New York Connecticut 125-35 Delaware 61-0 Colorado West Virginia 132-0 91-9 North Carolina Arizona Kentucky 125 ° 86-0 Tennessee 121-0 Arkansas Georgia 207-1 Oklahoma New Mexico 87-23 Téxas To date, twenty-one states, the Territory of Puerto Rico, and the District of Columbia. including neighboring Tennessee, Kentucky, Georgia, North Carolina, West Virginia, and Virginia, have passed legislation to address

The Solution - Make All Copays Count

Patient advocacy groups are calling on South Carolina Legislators to enact bipartisan legislation to protect patients who rely on third-party cost-sharing assistance by ensuring that all payments – <u>made by the patient or on behalf of the patient – count towards the patient's deductible and out-of-pocket maximum.</u> "When calculating enrollees contributions to any applicable cost sharing requirement, an insurer shall include any cost sharing amount paid by the enrollee or on behalf of an enrollee by another person." **These assistance programs are critical for patients with complex, chronic conditions and rare diseases with high cost treatment medications that** https://doi.org/10.1001/journal.org/

Patient Assistance Programs help patients better access their treatment medications, stay adherent, and provide positive health care outcomes. Many third-party entities, including pharmaceutical manufacturers, offer cost-sharing assistance. Historically, commercial health insurance plans counted this assistance towards a patient's deductible and maximum out-of-pocket, providing relief from high-cost sharing and making it possible for patients to afford their medicines.

Co-Sponsors of H.3934 & S.330 - Bipartisan Legislation

Listed are our 2025 Legislative Session supporters. Please join them in co-sponsoring this year's bills.

House of Representatives

Rep. Kevin Hardee (R-105th) Rep. Carla Schuessler (R-61st) Rep. Terry Alexander (D-59th) Rep. Carl Anderson (D-103rd) Rep. Frank Atkinson (D-57th) Rep. William Bailey (R-104th) Rep. Nathan Ballentine (R-71st) Rep. Bruce Bannister (R-24th) Rep. Heather Bauer (D-75th) Rep. Thomas Beach (R-10th) Rep. Beth E. Bernstein (D-78th) Rep. Phillip Bowers (R-3rd) Rep. Jeff Bradley (R-123rd) Rep. Gary Brewer (R-114th) Rep. Case Brittain (R-107th) Rep. James Burns (R-17th) Rep. Joseph Bustos (R-112th) Rep. Michah Caskey (R-89) Rep. Don Chapman (R-8th) Rep. William Chumley (R-35th) Rep. William Clyburn (D-82nd) Rep. Gilda Cobb-Hunter (D-95th) Rep. Neal Collins (R-5th) Rep. Bobby Cox (R-89th) Rep. Brandon Cox (R-92nd) Rep. Heather Crawford (R-68th) Rep. Sylleste Davis (R-100th) Rep. Chandra Dillard (D-23rd) Rep. Adam Duncan (R-2nd) Rep. Sarita Edgerton (R-34th)

Rep. Shannon Erickson (R-124th) Rep. Cal Forrest, Jr. (R-39th) Rep. Craig Gagnon (R-11th) Rep. Kambrell Garvin (D-77th) Rep. Gil Gatch (R-94th) Rep. Daniel Gibson (R-12th) Rep. Doug Gilliam (R-42nd) Rep. Lee Gilreath (R-7th) Rep. Hamilton Grant (D-79th) Rep. Val Guest (R-106th) Rep. Brandon Guffey (R-48th) Rep. Patrick Haddon (R-19) Rep. Bill Hager (R-122nd) Rep. Christopher Hart (D-73) Rep. Tom Hartnett (R-110th) Rep. Charles Hartz (R-81st) Rep. Jackie Hayes (D-55th) Rep. Rosalyn D. Henderson-Myers, Ph.D. (D-31st) Rep. William Herbkersman (R-118th) Rep. William Hewitt (R-108th) Rep. Davey Hiott (R-4th) Rep. William Hixon (R-83rd) Rep. Harriet Holman (R-102nd) Rep. Lonnie Hosey (D-91st) Rep. Chris Huff (R-28th)

Rep. Jay Jordan (R-63rd)

Rep. Jeffrey Johnson (R-58th)

Rep. Wendell Jones (D-25th)

Rep. Jay Kilmartin (R-85th)

Rep. Jermaine Johnson (D-52nd)

Rep. John King (D-49th) Rep. Roger Kirby (D-101st) Rep. Kathy Landing (R-80th) Rep. Brian Lawson (R-30th) Rep. Randy Ligon (R-43rd) Rep. Phillip Lowe (R-60th) Rep. Jason Luck (D-54th) Rep. John Mccravy (R-13th) Rep. Annie McDaniel (D-41st) Rep. Timothy McGinnis (R -56th) Rep. Cody Mitchell (R-65th) Rep. W. Scott Montgomery (R-32nd) Rep. Dennis C. Moss (R-29th) Rep. Mike Neese (R-44th) Rep. Brandon Newton (R-45th) Rep. Weston Newton (R-120th) Rep. Melissa Oremus (R-84th) Rep. Jordan Pace (R-117th) Rep. Fawn Pedalino (R-64th) Rep. Thomas Pope (R-47th) Rep. Paula Rawl Calhoon (R-87th) Rep. Robert Reese (D-70th) Rep. Michael Rivers (D-121st) Rep. Robby Robbins (R-97th) Rep. Seth Rose (D-72nd) Rep. Todd Rutherford (D-74th)

Rep. Blake Sanders (R-9th)

Rep. Mark Smith (R-99th)

Rep. Heath Sessions (R-46th)

Rep. Tiffany Spann-Wilder (D-109th)

Rep. Christopher Wooten (R-69th)
Rep. Richard Yow (R-53rd)

Senate

Sen. Michael Gambrell (R-2nd)
Sen. Jason Elliott (R-6th)
Sen. Karl Allen (D-7th)
Sen. Allen Blackmon (R-27th)
Sen. Greg Hembree (R-28th)
Sen. Everett Stubbs (R-17th)
Sen. Ross Turner (R-8th)
Sen. Tom Young (R-24th)
Sen. Russell Ott (D-26th)
Sen. Billy Garrett (R-10th)
Sen. Larry Grooms (R-37th)
Sen. Carlisle Kennedy (R-23rd)

Rep. Leonidas Stavrinakis (D-119th)

Rep. Bill Taylor (R-86th)

Rep. James Teeple (R-116th) Rep. Jackie R. Terribile (R-66th)

Rep. David Vaughan (R-27th)

Rep. William Whitmire (R-1st)

Rep. Paul Wickensimer (R-22nd)

Rep. Robert Williams (D-62nd)

Rep. Elizabeth Wetmore (D-115th)

Rep. David Weeks (D-51st)

Rep. Joe White (R-40th)

Rep. Mark Willis (R-16th)

Patient advocacy groups advocating on behalf of patient assistance













































Unfortunately, 5 out 6 of South Carolina Marketplace Plans and PBMs have adopted Polices, often referred to as "accumulator adjustment programs" that block assistance from counting towards a patient's deductible and maximum out-of-pocket limits.



SC House 3934 and Senate Bill 330

Patient advocacy groups are calling on South Carolina Legislators to support bipartisan legislation to address rising out-of-pocket costs from emerging insurance practices like "Accumulator Adjustment Programs" (AAP). Drug manufacturers, health foundations, charities, and nonprofit organizations help patients with assistance programs that cover the high out-of-pocket costs patients are required to pay. These Patient Assistance Programs are critical for patients living with the high cost of treatment for chronic, complex conditions and rare diseases that have no generic drug options.